Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Thomas Andrew Gaziano, M.D.

Co-Author

This page shows the publications co-authored by Thomas Gaziano and Ankur Pandya.
Connection Strength

4.794
  1. Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels. JAMA Netw Open. 2018 09 07; 1(5):e182008.
    View in: PubMed
    Score: 0.778
  2. Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. Med Decis Making. 2017 10; 37(7):802-814.
    View in: PubMed
    Score: 0.709
  3. Cost-effectiveness of Statin Therapy for ASCVD--Reply. JAMA. 2015 Nov 24; 314(20):2191-2.
    View in: PubMed
    Score: 0.641
  4. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA. 2015 Jul 14; 314(2):142-50.
    View in: PubMed
    Score: 0.625
  5. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):25-32.
    View in: PubMed
    Score: 0.563
  6. A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One. 2011; 6(5):e20416.
    View in: PubMed
    Score: 0.470
  7. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019 08; 214:77-87.
    View in: PubMed
    Score: 0.204
  8. Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations. Glob Heart. 2016 Mar; 11(1):37-46.e2.
    View in: PubMed
    Score: 0.163
  9. Cardiovascular Disease Screening By Community Health Workers Can Be Cost-Effective In Low-Resource Countries. Health Aff (Millwood). 2015 Sep; 34(9):1538-45.
    View in: PubMed
    Score: 0.158
  10. Increasing Prescription Length Could Cut Cardiovascular Disease Burden And Produce Savings In South Africa. Health Aff (Millwood). 2015 Sep; 34(9):1578-85.
    View in: PubMed
    Score: 0.158
  11. More americans living longer with cardiovascular disease will increase costs while lowering quality of life. Health Aff (Millwood). 2013 Oct; 32(10):1706-14.
    View in: PubMed
    Score: 0.138
  12. Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations. BMC Med. 2013 Jul 24; 11:170.
    View in: PubMed
    Score: 0.136
  13. Guidance for a causal comparative effectiveness analysis emulating a target trial based on big real world evidence: when to start statin treatment. J Comp Eff Res. 2019 09; 8(12):1013-1025.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.